Human LRRK2 protein with a I2020T mutation, also known as PARK8, RIPK7, and ROCO2, GenBank Accession No. NM_198578, amino acids 968-end, with an N-terminal GST-tag, expressed in an SF9cell expression system. MW = 210 kDa.
Human LRRK2 protein with a R1441C mutation, also known as PARK8, RIPK7, and ROCO2, GenBank Accession No. NM_198578, amino acids 968-end, with an N-terminal GST-tag, expressed in an SF9cell expression system. MW = 210 kDa.
Human LRRK2 protein with a R1441G mutation, also known as PARK8, RIPK7, and ROCO2, GenBank Accession No. NM_198578, amino acids 968-end, with an N-terminal GST-tag, expressed in an SF9cell expression system. MW = 210 kDa.
Human LRRK2 protein with a R1441H mutation, also known as PARK8, RIPK7, and ROCO2, GenBank Accession No. NM_198578, amino acids 968-end, with an N-terminal GST-tag, expressed in an SF9cell expression system. MW = 210 kDa.
Human LRRK2 protein with a Y1699C mutation, also known as PARK8, RIPK7, and ROCO2, GenBank Accession No. NM_198578, amino acids 968-end, with an N-terminal GST-tag, expressed in an SF9cell expression system. MW = 210 kDa.
Human LRRK2 protein with a Y1699G mutation, also known as PARK8, RIPK7, and ROCO2, GenBank Accession No. NM_198578, amino acids 968-end, with an N-terminal GST-tag, expressed in an SF9 cell expression system. MW = 210 kDa.
Human LRRK2, also known as PARK8, RIPK7, and ROCO2, GenBank Accession No. NM_198578, amino acids 968-end, with an N-terminal GST-tag, expressed in an SF9 cell expression system. MW = 210 kDa.
Human JNK1-β1(K55M), also known as MAPK8 (K55M) (GenBank Accession No. NM_139046), full length with mutation of lysine55 to methionine, and N-terminal GST-tag, MW=~70 kDa, expressed in E. coli. The K55M mutation prevents ATP binding, making the kinase inactive.
